Unlabelled: Age-related macular degeneration (AMD) is a disease with significant visual morbidity and accounts for the majority of blind registrations in the developed world including the UK. Certain forms of neovascular AMD are amenable to treatment but require expeditious referral to a retinal specialist.
Aim: To evaluate the possibility of using nonstereo fundus photographs as a low-cost screening tool for neovascular AMD.
Design: Retrospective review of patients referred to the macular clinic of a teaching hospital in London.
Methods: A total of 198 randomised digital fundus photographs, without any other clinical information, were presented to two independent ophthalmic interns who graded them into one of the three categories: normal, age-related maculopathy (ARM), or neovascular age-related macular degeneration (AMD) to determine the urgency of referral to clinic. The results were compared with the known diagnosis for each patient and sensitivities and specificities for each diagnostic category calculated.
Results: The intraobserver Kappa statistic was 0.75 and 0.91 for grader 1 and 2, respectively. The interobserver Kappa was 0.54. The mean sensitivity and specificity for the identification of ARM was 60.5 and 76.3%, respectively The mean sensitivity and specificity for the identification of AMD was 85.7 and 78.8%, respectively.
Conclusion: Nonstereo digital fundus photograph is a reasonable screening tool for CNV and may aid in decreasing the visual morbidity it causes by enabling timely referrals and treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/sj.eye.6701916 | DOI Listing |
Vestn Oftalmol
December 2024
West Siberian Institute of Postgraduate Medical Education, Tyumen, Russia.
Age-related macular degeneration (AMD) is a chronic multifactorial degenerative eye disease and one of the leading causes of irreversible blindness worldwide. Despite extensive research, there is no consensus on the predominant pathological mechanism leading to photoreceptor death. AMD is associated with molecular and cellular disruptions that ultimately result in photoreceptor degeneration.
View Article and Find Full Text PDFThe introduction of faricimab, a drug targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2, has enabled the implementation of the highly effective dual inhibition strategy in real clinical practice for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both previously treated with intravitreal injections and newly diagnosed. This article presents a series of 11 clinical cases involving patients with nAMD and DME who received loading doses of faricimab and continued ophthalmological observation. Among them, three patients with nAMD and two with DME were treatment-naïve, while the others were switched from alternative therapies to faricimab.
View Article and Find Full Text PDFPurpose: This study evaluates the efficacy of intravitreal injections (IVI) of faricimab in patients with neovascular age-related macular degeneration (nAMD) and retinal pigment epithelium detachment (RPED) resistant to other anti-VEGF agents.
Material And Methods: The study included 61 patients (61 eyes) with nAMD previously treated with aflibercept and/or brolucizumab IVIs. Three groups were formed: group 1 received aflibercept IVI (32 eyes), group 2 received brolucizumab IVI (14 eyes), and group 3 received aflibercept followed by brolucizumab IVI (15 eyes).
Vestn Oftalmol
December 2024
Novosibirsk State Regional Hospital, Novosibirsk, Russia.
Purpose: This study evaluated the impact of phacoemulsification cataract surgery (PE) on anatomical and functional parameters, as well as the regimen and frequency of anti-VEGF injections in patients with neovascular age-related macular degeneration (nAMD) over a long-term period (up to 3 years).
Material And Methods: The study included 117 patients (117 eyes) diagnosed with nAMD and cataract, graded by LOCS: LOCS I (=56; 47.9%), LOCS II (=57; 48.
Eye (Lond)
December 2024
Department of Ophthalmology and Vision Science, University of Toronto, Suite 400, 340 College Street, Toronto, ON, M5T 3A9, Canada.
Background/objectives: To investigate demographic enrolment characteristics in age-related macular degeneration (AMD) trials.
Subjects/methods: Clinicaltrials.gov was searched with "age-related macular degeneration" to identify RCTs with double, triple, or quadruple masking.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!